News | November 05, 2021
Prime Therapeutics to list Semglee and Insulin Glargine
Biocon Biologics and Viatris co-developed the products
Biocon Biologics and Viatris co-developed the products
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The centralized marketing authorization granted by the EC is valid in all EU Member
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
If approved, DTX401 would be the first treatment to address the disease at its root cause
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
